SYS6023 / CSPC Pharma - LARVOL DELTA

First-in-human study of SYS6023 in patients (pts) with malignant solid tumors (ESMO 2026) - No abstract available

Clinical • First-in-human • P1 data • Oncology • Solid Tumor

A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting ➔ Recruiting | N=114 ➔ 36

Enrollment change • Enrollment open • Breast Cancer • Oncology • Solid Tumor

A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer (clinicaltrials.gov) - P2 | N=114 | Not yet recruiting | Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

New P2 trial • Breast Cancer • Oncology • Solid Tumor

A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=400 | Recruiting | Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Profiles, and Preliminary Efficacy of SYS6023 in Patients with Advanced Solid Tumors (ChiCTR) - P1 | N=388 | Recruiting | Sponsor: Shanghai Chest Hospital; CSPC Megalith Biopharmaceutical Co., Ltd

Metastases • New P1 trial • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer • ALK • BRAF • ER • ERBB3 • KRAS • MET • NRG1 • NTRK • PGR • ROS1

SYS6023 received FDA clinical trial approval, and Sinopharm increased its investment in the innovative biological drug market [Google translation] (Eastmoney.com) - "On July 9, Sinopharm announced that its holding subsidiary, CSPC Pharmaceutical Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as Jushi Biopharmaceutical), recently received a notice from the U.S. Food and Drug Administration (FDA) that the clinical trial application for the injectable drug SYS6023 submitted by Jushi Biopharmaceutical has been approved by the U.S. FDA and can conduct clinical trials in the United States."

IND • Oncology • Solid Tumor

Another product approved for clinical use! Inventory of CSPC Pharmaceutical Group’s ADC pipeline under development [Google translation] (163.com) - "On March 20, CSPC announced that another antibody drug conjugate (ADC) of the company, SYS6023, had been approved for clinical use in China and is planned to be developed to treat patients with advanced solid tumors."

New trial • Oncology • Solid Tumor